The FDA recently approved a new weight-loss pill called Foundayo, developed by Eli Lilly. This pill is notable as it’s the second oral GLP-1 medication to hit the market, expanding the options for those looking to manage obesity.
Foundayo stands out because it can be taken any time of day without needing to coordinate with meals. This is different from another pill, Wegovy, which must be taken 30 minutes before eating or drinking. Dr. Dan Skovronsky, Lilly’s chief scientist, emphasized that Foundayo aims to fit easily into people’s daily lives.
Recent estimates show that about 400,000 people in the U.S. are already using Wegovy. This medication’s popularity hasn’t waned despite needing specific timing for ingestion. Foundayo, consequently, could attract individuals who are hesitant about injections or those seeking more flexible pill options.
Pricing is also shifting with these new medications. Foundayo will start at $149 monthly for lower doses, which is a significant decrease compared to former costs. For higher doses, it could go up to $349, but there are options that could reduce costs for insured patients, possibly to as little as $25. Medicare will also cover it for some patients starting July 1, with copays capped at $50.
Skovronsky shared the goal of making obesity treatments accessible to more people. Research shows that many who could benefit from weight-loss medications are not currently using available options. This pill may appeal to those who experience less severe obesity and prefer not to try weekly injections.
Clinical trials showed that participants using the highest dose of Foundayo lost an average of 12% of their body weight over 72 weeks, while those on a placebo only lost 0.9%. Other GLP-1 medications have shown even higher weight loss rates, attracting attention from both doctors and patients.
Switching from injections to Foundayo also appears effective. Research indicates individuals who transitioned maintained weight loss better than those who switched from other medications. Common side effects include nausea and constipation, mirroring other drugs in the same class.
While Foundayo is approved for adults, safety hasn’t been established for children or during pregnancy. There are also considerations for women on birth control, as this drug may affect the effectiveness of those pills.
The swift approval of Foundayo took just 50 days under a special FDA program aimed at fast-tracking essential treatments. Historically, new drugs usually take several months longer to get the green light.
As more people turn to social media to share their weight-loss journeys and experiences with these medications, it’s clear that GLP-1 drugs are making waves in the healthcare landscape. With findings suggesting about 70% of Americans are struggling with obesity, medications like Foundayo and Wegovy are significant steps forward in addressing this ongoing public health issue.
